Results 51 to 60 of about 201,288 (355)

A DNA Vaccine That Encodes an Antigen-Presenting Cell-Specific Heterodimeric Protein Protects against Cancer and Influenza

Molecular Therapy: Methods & Clinical Development, 2020
Immunogenicity of DNA vaccines can be increased by constructing the DNA in such a way that it encodes secreted homodimeric fusion proteins that target antigen-presenting cells (APCs). In this study, we have developed novel APC-targeting vaccine molecules
Ranveig Braathen, Heidi Cecilie Larsen Spång, Daniëla Maria Hinke, Jana Blazevski, Sonja Bobic, Even Fossum, Bjarne Bogen   +6 more
doaj  

A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade

Viruses, 2020
On average, there are 3–5 million severe cases of influenza virus infections globally each year. Seasonal influenza vaccines provide limited protection against divergent influenza strains.
Brigette N. Corder, Brianna L. Bullard, Gregory A. Poland, Eric A. Weaver   +3 more
doaj   +1 more source

Vaccines for Pandemic Influenza

Emerging Infectious Diseases, 2006
Recent outbreaks of highly pathogenic avian influenza in Asia and associated human infections have led to a heightened level of awareness and preparation for a possible influenza pandemic. Vaccination is the best option by which spread of a pandemic virus could be prevented and severity of disease reduced.
Luke, CJ, Subbarao, K
openaire   +4 more sources

Recombinant Influenza Vaccines [PDF]

Acta Naturae, 2012
This review covers the problems encountered in the construction and production of new recombinant influenza vaccines. New approaches to the development of influenza vaccines are investigated; they include reverse genetics methods, production of virus-like particles, and DNA- and viral vector-based vaccines.
Sedova, E., Shcherbinin, D., Migunov, A., Smirnov, Iu, Logunov, D., Shmarov, M., Tsybalova, L., Naroditskiĭ, B., Kiselev, O., Gintsburg, A.   +9 more
openaire   +4 more sources

Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection [PDF]

, 2017
The emergence of multiple novel lineages of H1 and H3 influenza A viruses in swine has confounded control by inactivated vaccines. Because of substantial genetic and geographic heterogeneity among circulating swine influenza viruses, one vaccine strain ...
Claes, Gerwin, Cox, Eric, Krammer, Florian, Mancera Gracia, José Carlos, Qiu, Yu, Sys, Lieve, Trus, Ivan, Van Reeth, Kristien, Versnaeyen, Han   +8 more
core   +2 more sources

Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases

European Journal of Heart Failure, Volume 24, Issue 11, Page 2000-2018, November 2022., 2022
Overview on incidence, diagnosis, and therapy in vaccine‐related myocarditis. CMR, cardiac magnetic resonance; EMB, endomyocardial biopsy; NSAIDS, non‐steroidal anti‐inflammatory drugs. Abstract Over 10 million doses of COVID‐19 vaccines based on RNA technology, viral vectors, recombinant protein, and inactivated virus have been administered worldwide.
Bettina Heidecker, Noa Dagan, Ran Balicer, Urs Eriksson, Giuseppe Rosano, Andrew Coats, Carsten Tschöpe, Sebastian Kelle, Gregory A. Poland, Andrea Frustaci, Karin Klingel, Pilar Martin, Joshua M. Hare, Leslie T. Cooper, Antonis Pantazis, Massimo Imazio, Sanjay Prasad, Thomas F. Lüscher   +17 more
wiley   +1 more source

Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses

Scientific Reports, 2021
While vaccines remain the best tool for preventing influenza virus infections, they have demonstrated low to moderate effectiveness in recent years. Seasonal influenza vaccines typically consist of wild-type influenza A and B viruses that are limited in ...
James D. Allen, Ted M. Ross
doaj   +1 more source

Antigen targeting to dendritic cells: Still a place in future immunotherapy?

European Journal of Immunology, Volume 52, Issue 12, Page 1909-1924, December 2022., 2022
Dendritic cell‐based immunotherapy is a promising vaccination strategy to treat infectious diseases, autoimmunity, and cancer. In this review, we present an overview on the current state of antigen targeting approaches via C‐type lectin receptors, with an outlook on future developments and potential for clinical translation.
Patrizia Stoitzner, Nikolaus Romani, Christoph Rademacher, Hans Christian Probst, Karsten Mahnke   +4 more
wiley   +1 more source

IL‐4/IL‐13‐producing ILC2s are required for timely control of intestinal helminth infection in mice

European Journal of Immunology, Volume 52, Issue 12, Page 1925-1933, December 2022., 2022
ILC2‐derived IL‐4/IL‐13 plays a non‐redundant role for eosinophil recruitment to the lung and expulsion of N. brasiliensis worm parasites from the intestine. Abstract Infection of mice with Nippostrongylus brasiliensis (Nb) serves as a model for human hookworm infection affecting about 600 million people world‐wide.
Filipa Varela, Cornelia Symowski, Jonathan Pollock, Stefan Wirtz, David Voehringer   +4 more
wiley   +1 more source

Agent-based model of the impact of higher influenza vaccine efficacy on seasonal influenza burden

Vaccine: X, 2023
Introduction: Current influenza vaccines have limited effectiveness. COVID-19 vaccines using mRNA technology have demonstrated very high efficacy, suggesting that mRNA vaccines could be more effective for influenza. Several such influenza vaccines are in
Mary G. Krauland, Richard K. Zimmerman, Katherine V. Williams, Jonathan M. Raviotta, Lee H. Harrison, John V. Williams, Mark S. Roberts   +6 more
doaj